Bluejay Diagnostics (BJDX) 10-Q 15 May 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 01, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Entity Information [Line Items]
Entity Registrant Name	Bluejay Diagnostics, Inc.
Entity Central Index Key	0001704287
Entity File Number	001-41031
Entity Tax Identification Number	47-3552922
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	360 Massachusetts Avenue
Entity Address, Address Line Two	Suite 203
Entity Address, City or Town	Acton
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01720
Entity Phone Fax Numbers [Line Items]
City Area Code	(844)
Local Phone Number	327-7078
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock
Trading Symbol	BJDX
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		2,904,448

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,661,169	$ 2,208,516
Prepaid expenses and other current assets	788,578	747,263
Deferred offering costs		265,081
Total current assets	3,449,747	3,220,860
Property and equipment, net	1,301,460	1,285,741
Operating lease right-of-use assets	298,655	333,267
Other non-current assets	25,215	28,663
Total assets	5,075,077	4,868,531
Current liabilities:
Accounts payable	271,825	491,474
Operating lease liability, current	145,811	162,990
Accrued expenses and other current liabilities	1,108,105	1,116,911
Total current liabilities	1,525,741	1,771,375
Operating lease liability, non-current	170,703	189,987
Other non-current liabilities	11,407	12,321
Total liabilities	1,707,851	1,973,683
Commitments and Contingencies (See Note 13)
Stockholders’ equity:
Common stock, $0.0001 par value; 7,500,000 shares authorized; 2,688,448 and 1,239,140 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	269	124
Additional paid-in capital	32,646,412	29,845,714
Accumulated deficit	(29,279,455)	(26,950,990)
Total stockholders’ equity	3,367,226	2,894,848
Total liabilities and stockholders’ equity	$ 5,075,077	$ 4,868,531

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	7,500,000	7,500,000
Common stock, shares issued	2,688,448	1,239,140
Common stock, shares outstanding	2,688,448	1,239,140

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 1,334,797	$ 1,354,549
General and administrative	1,086,884	1,176,977
Sales and marketing	6,424	148,046
Total operating expenses	2,428,105	2,679,572
Operating loss	(2,428,105)	(2,679,572)
Other income:
Other income, net	99,640	139,729
Total other income	99,640	139,729
Net loss	$ (2,328,465)	$ (2,539,843)
Net loss per share - Basic (in Dollars per share)	$ (0.99)	$ (2.49)
Weighted average common shares outstanding:
Weighted average common shares outstanding Basic (in Shares)	2,359,376	1,018,755

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net loss per share - Diluted	$ (0.99)	$ (2.49)
Weighted average common shares outstanding Diluted	2,359,376	1,018,755

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2022	$ 101	$ 28,538,274	$ (16,997,102)	$ 11,541,273
Balance (in Shares) at Dec. 31, 2022	1,010,560
Stock-based compensation expense		54,730		54,730
Grants of fully vested restricted stock units to settle accrued bonus, net of shares withheld	$ 1	107,234		107,235
Grants of fully vested restricted stock units to settle accrued bonus, net of shares withheld (in Shares)	12,188
Net loss			(2,539,843)	(2,539,843)
Balance at Mar. 31, 2023	$ 102	28,700,238	(19,536,945)	9,163,395
Balance (in Shares) at Mar. 31, 2023	1,022,748
Balance at Dec. 31, 2023	$ 124	29,845,714	(26,950,990)	$ 2,894,848
Balance (in Shares) at Dec. 31, 2023	1,239,140			1,239,140
Stock-based compensation expense		11,874		$ 11,874
Issuance of Common Stock and PreFunded Warrants net of issuance costs of $444,950	$ 71	2,788,898		2,788,969
Issuance of Common Stock and PreFunded Warrants net of issuance costs of $444,950 (in Shares)	712,538
Exercise of PreFunded Warrants	$ 74	(74)
Exercise of PreFunded Warrants (in Shares)	736,770
Net loss			(2,328,465)	(2,328,465)
Balance at Mar. 31, 2024	$ 269	$ 32,646,412	$ (29,279,455)	$ 3,367,226
Balance (in Shares) at Mar. 31, 2024	2,688,448			2,688,448

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) (Parentheticals)	3 Months Ended
	Mar. 31, 2024 USD ($)
PreFunded Warrants
Net of issuance costs	$ 444,950

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (2,328,465)	$ (2,539,843)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	19,714	120,017
Stock-based compensation expense	11,874	219,589
Amortization of right-of-use asset	34,612	40,328
Non-cash interest expense for finance lease	294
Changes in operating assets and liabilities:
Deferred offering costs	265,081
Prepaid expenses and other current assets	(41,315)	(446,532)
Other non-current assets	3,448	1,768
Accounts payable	(219,649)	(314,773)
Other non-current Liabilities	(20,492)
Accrued expenses and other current liabilities	(21,178)	(14,161)
Net cash used in operating activities	(2,296,076)	(2,933,607)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(35,433)	(340,669)
Net cash used in investing activities	(35,433)	(340,669)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, gross	3,500,000
Payment of issuance costs of common stock	(445,950)
Payment of deferred offering costs	(265,081)
Payment of finance lease	(4,807)	(1,202)
Payment of tax withholding obligations on restricted stock units		(57,601)
Net cash provided in financing activities	2,784,162	(58,803)
Increase (decrease) in cash and cash equivalents	452,653	(3,333,079)
Cash and cash equivalents, beginning of period	2,208,516	10,114,990
Cash and cash equivalents, end of period	2,661,169	6,781,911
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION AND NON-CASH FINANCING ACTIVITIES
Liabilities incurred for the purchase of property and equipment		$ 67,000

Nature of Operations and Basis

Nature of Operations and Basis of Presentation	3 Months Ended
	Mar. 31, 2024
Nature of Operations and Basis of Presentation [Abstract]
NATURE OF OPERATIONS AND BASIS OF PRESENTATION	1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION Business Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”) is a medical diagnostics company developing rapid tests using whole blood on our Symphony technology platform (“Symphony”) to improve patient outcomes in critical care settings. The Company’s Symphony platform is a combination of Bluejay’s intellectual property (“IP”) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges that if cleared, authorized, or approved by the U.S. Food and Drug Administration (the “FDA”), can provide a solution to a significant market need in the United States. Clinical trials indicate the Symphony device produces results in less than 20 minutes for intensive care units and emergency rooms, where rapid and reliable results are required. Bluejay’s first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings. IL-6 is a clinically established inflammatory biomarker, considered a ‘first-responder,’ for assessment of severity of infection and inflammation across many disease indications, including sepsis. A current challenge of healthcare professionals is the excessive time and cost associated determining a patient’s level of severity at triage and the Symphony IL-6 test has the ability to consistently monitor this critical care biomarker with rapid results. In the future Bluejay plans to develop additional tests for Symphony including two cardiac biomarkers (hsTNT and NT pro-BNP), as well as other tests using the Symphony platform. The Company does not yet have regulatory clearance for its Symphony products, and its Symphony products will need to receive regulatory authorization from the FDA in order to be marketed as a diagnostic product in the United States. We were incorporated under the laws of Delaware on March 20, 2015. Our headquarters is located in Acton, Massachusetts. On June 4, 2021, the Company formed Bluejay Spinco, LLC, a wholly owned subsidiary of the Company, for purposes of further development of the Company’s ALLEREYE diagnostic test. ALLEREYE is a point-of-care device offering healthcare providers a solution for diagnosing Allergic Conjunctivitis. FDA Regulatory and Clinical Trial Update Our current regulatory strategy is designed to support commercialization of Symphony in the United States pending marketing authorization from the FDA. Previously, our regulatory strategy involved clinical studies involving COVID-19 patients. However, we have shifted our focus away from COVID-19 patients due to a significant decline in the number of COVID-19 related hospitalizations. Pursuant to this revised strategy, we are in the process of completing In the first quarter of 2024, we initiated multicenter SYmphony IL-6 MONitoring Sepsis (“SYMON”) clinical studies investigating the role of interleukin-6 (IL-6) in patients diagnosed with sepsis and septic shock. This prospective study aims to assess the performance of IL-6 upon initial presentation to the intensive care unit (ICU). A preliminary analysis of the SYMON-I pilot clinical study (registered clinical trial number NCT06181604) highlighted that baseline levels of IL-6 are strongly associated with both in-hospital (40 survivors, 7 non-survivors) and 28-day mortality (31 survivors, 7 non-survivors) among sepsis patients. In contrast, baseline Sequential Organ Failure Assessment (SOFA) score which is used to assess organ dysfunction in sepsis patients did not predict in-hospital or 28-day mortality. We believe that the findings underscore the potential importance of IL-6 as a predictor and provide new insights into the potential pathways for improving sepsis outcomes. Following these results, we are planning next steps in our clinical study process, which include a final analysis of the SYMON-I clinical study dataset upon completion of the study. Subject to our ability to remain a going concern, we intend to present the data at a future national scientific meeting and publish in peer-reviewed publications. The final results from the SYMON-I clinical study would inform the SYMON-II validation study, which we would plan to use to support a 510(k) application, which we are targeting for submission in 2025. Risks and Uncertainties The Company is subject to a number of risks similar to other companies in its industry, including rapid technological change, competition from larger biotechnology companies and dependence on key personnel. The Company is also impacted by inflationary pressures and global supply chain disruptions currently impacting many companies. Our common stock currently is listed for quotation on the Nasdaq Capital Market. We are required to meet specified financial requirements in order to maintain such listing, including a requirement that the bid price for our common stock remain above $1.00, and that the market value of our publicly held securities be at least $1 million. On February 28, 2024, we received a notification letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) notifying us that the closing bid price for our common stock had been below $1.00 for the previous 30 consecutive business days and that we therefore are not in compliance with the minimum bid price requirement for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification has no immediate effect on the listing of our common stock on the Nasdaq Capital Market. Under the Nasdaq Listing Rules, we have a period of 180 calendar days to regain compliance. To regain compliance, the closing bid price of our common stock must be at least $1.00 or higher for a minimum of ten consecutive business days, and in such case, Nasdaq will provide us with written confirmation of compliance. If we do not regain compliance by August 26, 2024, we may be eligible for an additional 180 calendar days, provided that we meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq, except the bid price requirement. If we are not eligible or it appears to Nasdaq that we will not be able to cure the deficiency during the second compliance period, Nasdaq will provide written notice to us that our common stock will be subject to delisting. In the event of such notification, we may appeal Nasdaq’s determination to delist its securities, but there can be no assurance that Nasdaq would grant our request for continued listing. We intend to take all reasonable measures available to us to achieve compliance to allow for continued listing on the Nasdaq Capital Market. However, there can be no assurance that we will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria. If our common stock does not regain compliance with the minimum price requirement during the applicable compliance period, we may need to effect a reverse stock split, whereby shares of our common stock are consolidated so that the per-share trading price becomes greater than $1.00 per share. At our annual meeting of stockholders on May 14, 2024, our shareholders provided our Board of Directors with authority to implement such a reverse stock split, and our Board of Directors is currently evaluating whether and when to implement such a reverse stock split. As of the close of business on May 9, 2024, the market value of our publicly held common stock (which is our only outstanding class of securities) was approximately $1.25 million. If the value of our publicly held common stock declines below $1 million, we would also be subject to Nasdaq delisting proceedings on that basis. If our common stock is delisted, we may seek to have our common stock quoted on an over-the-counter marketplace, such as on the OTCQX. The OTCQX is not a stock exchange, and if our common stock trades on the OTCQX rather than a securities exchange, there may be significantly less trading volume and analyst coverage of, and significantly less investor interest in, our common stock, which may lead to lower trading prices for our common stock. Any potential delisting of our common stock from the Nasdaq Capital Market may have materially adverse consequences to our stockholders, including: ● A reduced market price and liquidity with respect to our shares of common stock, which could make our ability to raise new investment capital more difficult; ● limited dissemination of the market price of our common stock; ● limited news coverage; ● limited interest by investors in our common stock; ● volatility of the prices of our common stock, due to low trading volume; ● our common stock being considered a “penny stock,” which would result in broker-dealers participating in sales of our common stock being subject to the regulations set forth in Rules 15g-2 through 15g-9 promulgated under the Exchange Act; ● increased difficulty in selling our common stock in certain states due to “blue sky” restrictions; and ● limited ability to issue additional securities or to secure additional financing. On July 24, 2023, the Company executed a reverse stock split of its shares of common stock at a ratio of 1-for-20 (the “Reverse Stock Split”), with a corresponding reduction in the number of authorized outstanding number of shares of common stock from 100,000,000 to 7,500,000. The Reverse Stock Split became effective on July 24, 2023. All of the Company’s 2023 historical share and per share information related to issued and outstanding common stock and outstanding options and warrants exercisable for common stock in these financial statements have been adjusted, on a retroactive basis, to reflect this 1-for-20 reverse stock split. Going Concern Uncertainty The accompanying unaudited condensed consolidated financial statements for the three months ended March 31, 2024 and 2023 were prepared under the assumption that the Company will continue as a going concern, which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business. Our operations to date have been funded primarily through the proceeds of (i) our initial public offering (the “IPO”) in November 2021 (the “IPO Date”), (ii) the registered direct offering of common stock and concurrent private placement of warrants that we completed on August 28, 2023, and (iii) the public offering of common stock and warrants that we completed on January 2, 2024. As of March 31, 2024, the Company possessed cash and cash equivalents of approximately $2.7 million, while having current liabilities of approximately $1.5 million. During the quarter ended March 31, 2024, the Company’s net cash used in operating activities was approximately $2.3 million. The Company expects that it will need to raise a material amount of additional capital in the imminent near-term to continue its operations, and that absent such near-term funding, it will likely run out of available cash resources in the near-term. The Company’s board of directors has been exploring potential pathways for material financing, or other strategic alternatives, and to date, the board of directors has not been able to identify alternatives that it believes to be viable. If the Company is unable to obtain financing in the imminent future, the Company’s board of directors could determine to cause the Company to undertake a process of liquidation under Chapter 7 of applicable U.S. bankruptcy laws. In such event, the Company does not currently expect that holders of shares of common stock of the Company would recoup any material value in such process. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in conformity with generally accepted accounting principles in the United States (“US GAAP”) consistent with those applied in, and should be read in conjunction with, the Company’s audited financial statements and related footnotes for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K. The unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2024, its results of operations and cash flows for the three months ended March 31, 2024 and 2023, in accordance with US GAAP. The unaudited condensed consolidated financial statements do not include all of the information and footnotes required by US GAAP for complete financial statements, as allowed by the relevant U.S. Securities and Exchange Commission (“SEC”) rules and regulations; however, the Company believes that its disclosures are adequate to ensure that the information presented is not misleading. The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. The results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2024, or any other interim period within this fiscal year.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	2 . During the three months ended March 31, 2024, there were no changes to the significant accounting policies as described in the 2023 Audited Financial Statements. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in these condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. The Company believes judgment is involved in accounting for the fair value-based measurement of stock-based compensation, accruals, and warrants. The Company evaluates its estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the condensed consolidated financial statements. Stock-based compensation Stock-based compensation expense for all stock-based payment awards made to employees, directors and non-employees is measured based on the grant-date fair value of the award. Stock-based compensation expense for awards granted to non-employees is determined using the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. The Company uses the Black-Scholes option pricing model to determine the fair value of options granted. The Company recognizes the compensation cost of stock-based awards on a straight-line basis over the requisite service period. For stock awards for which vesting is subject to performance-based milestones, the expense is recorded over the implied service period after the point when the achievement of the milestone is probable, or the performance condition has been achieved. The Company recognizes forfeitures related to employee stock-based payments when they occur. Forfeited options are recorded as a reduction to stock compensation expense. Research and development expenses Costs incurred in the research and development of new products are expensed as incurred. Research and development costs include, but are not limited to, salaries, benefits, stock-based compensation, laboratory supplies, fees for professional service providers and costs associated with product development efforts, including preclinical studies and clinical trials. The Company estimates preclinical study and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf. Segment Reporting Management has determined that the Company has one operating segment, which is consistent with the Company structure and how it manages the business. As of March 31, 2024 and December 31, 2023, the majority of the Company’s assets were located in the United States. Net Loss per Share Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, convertible notes, options outstanding under the Company’s stock option plan and warrants. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive. Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti -dilutive are as follows (in common stock equivalent shares): Potentially Dilutive Securities Listing: March 31, 2024 2023 Options to purchase common stock 29,770 36,992 Restricted stock units (RSUs) 1,000 9,875 Warrants for common stock 271,714 40,594 Class A warrants for common stock 124,200 124,200 Class B warrants for common stock 3,770 3,770 5-Year warrants for common stock 2,692,308 - Prefunded warrants for common stock 1,243,000 - Recently Adopted Accounting Standards In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This amends the ASC 815 Derivatives and Hedging—Contracts in Entity’s Own Equity to simplify the guidance on (1) accounting for convertible instruments, and (2) the derivatives scope exception for contracts in an entity’s own equity. The guidance on earnings per share (“EPS”) has also been amended to simplify the calculations and make them more internally consistent. The Company adopted this new standard on January 1, 2024. The new standard had no impact on the Company’s condensed consolidated financial statements. Recently Issued Accounting Standards The Company does not believe that any recently issued but not yet effective accounting pronouncements will have a material effect on the accompanying unaudited condensed consolidated financial statements.

License and Supply Agreement wi

License and Supply Agreement with Toray Industries	3 Months Ended
	Mar. 31, 2024
License and Supply Agreement with Toray Industries [Abstract]
LICENSE AND SUPPLY AGREEMENT WITH TORAY INDUSTRIES	3. LICENSE AND SUPPLY AGREEMENT WITH TORAY INDUSTRIES On October 23, 2023, the Company and Toray entered into an Amended and Restated License Agreement (the “New Toray License Agreement”) and a Master Supply Agreement (the “New Toray Supply Agreement”). Under the New Toray License Agreement, the Company continues to license from Toray intellectual property rights needed to manufacture single-use test cartridges, and the Company has received the right to sublicense certain Toray intellectual property to Sanyoseiko in connection with Sanyoseiko’s ongoing agreement with the Company to manufacture its Symphony device and cartridges (including in connection with the Company’s clinical trials). In addition, the New Toray License Agreement provides for the transfer of certain technology related to the cartridges to Sanyoseiko. The royalty payments payable by the Company to Toray have been reduced under the New Toray License Agreement from 15% to 7.5% (or less in certain circumstances) of net sales of certain cartridges for a term of 10 years. A 50% reduction in the royalty rate applies upon expiry of applicable Toray patents on a product-by-product and country-by-country basis. The New Toray License Agreement contemplates that applicable royalty payment obligations from the Company to Toray for other products will be determined separately by the parties in the future. There were no sales of or revenues from the cartridges during the three month periods ended March 31, 2024 and 2023. Under the New Toray Supply Agreement, Toray is manufacturing (through its wholly owned subsidiary Kamakura Techno- Science, Inc.) certain product intermediate components for use in cartridges being manufactured for the Company by Sanyoseiko. These cartridges made using Toray intermediates are for the purpose of obtaining FDA approval and not for commercial sale. The New Toray Supply Agreement has a term ending on the earlier of October 23, 2025 or the date that the Company obtains FDA approval for its product, and may be extended for up to six months by mutual agreements of the parties. If FDA approval is obtained, Sanyoseiko will be required to manufacture the intermediates and cartridges under a separate supply agreement between the Company and Sanyoseiko. At March 31, 2024 and 2023, there were no amounts accrued related to the New Toray License Agreement.

Warrants

Warrants	3 Months Ended
	Mar. 31, 2024
Warrants [Abstract]
WARRANTS	4. WARRANTS The following table summarizes information with regard to warrants outstanding at March 31, 2024: Shares Exercisable for Weighted Weighted January 2024 Common Stock Warrants 2,692,308 Common Stock $ 1.30 4.8 January 2024 Placement Agent Warrants 188,462 Common Stock $ 1.625 4.8 January 2024 Prefunded Warrants 1,243,000 Common Stock $ 0.0001 – August 2023 Common Stock Warrants 216,000 Common Stock $ 7.365 4.4 August 2023 Placement Agent Warrants 15,120 Common Stock $ 9.2063 4.4 Class A Warrants 124,200 Common Stock $ 140.00 2.6 Class B Warrants 3,770 Common Stock $ 200.00 2.6 Other Pre-2024 Common Stock Warrants 40,594 Common Stock $ 64.73 1.9 January 2024 Common Stock Warrants, January 2024 Placement Agent Warrants and January 2024 Prefunded Warrants On January 2, 2024, the Company sold in a public offering (such transaction, the “January 2024 Offering”) (i) 537,768 shares of the Company’s common stock, and (ii) prefunded warrants to purchase up to an aggregate 2,154,540 shares of common stock (the “Prefunded Warrants”). The Shares and Prefunded Warrants were sold together with warrants to purchase up to an aggregate of 2,692,308 shares of Common Stock at an exercise price of $1.30 per share (the “January 2024 Warrants”). The combined public offering price was $1.30 per share of Common Stock and related January 2024 Warrant and $1.2999 per Prefunded Warrant and related January 2024 Warrant. The Prefunded Warrants are immediately exercisable and may be exercised at any time until all of the Prefunded Warrants are exercised in full. The January 2024 Warrants are exercisable immediately upon issuance for a period of five years following the date of issuance. Pursuant to an engagement letter, dated as of August 7, 2023, as amended October 11, 2023 (the “Placement Agent Engagement Letter”), by and between the Company and the H.C. Wainwright & Co., LLC, or the placement agent As of March 31, 2024, 911,540 of the Prefunded Warrants had been exercised, and between March 31, 2014 and the date of this filing (May 15, 2024), an additional 216,000 of the Prefunded Warrants were exercised.

Stock Compensation

Stock Compensation	3 Months Ended
	Mar. 31, 2024
Stock Compensation [Abstract]
STOCK COMPENSATION	5. STOCK COMPENSATION Stock Incentive Plans In 2018, the Company adopted the 2018 Stock Incentive Plan (the “2018 Plan”) for employees, consultants, and directors. The 2018 Plan, which is administered by the Board of Directors, permits the Company to grant incentive and nonqualified stock options for the purchase of common stock, and restricted stock awards. The maximum number of shares reserved for issuance under the 2018 Plan is 31,472. At March 31, 2024, there were 13,113 shares available for grant under the 2018 Plan. On July 6, 2021, the Company’s board of directors and stockholders approved and adopted the Bluejay Diagnostics, Inc. 2021 Stock Plan (the “2021 Plan”). A total of 98,000 shares of common stock were approved to be initially reserved for issuance under the 2021 Stock Plan. At March 31, 2024, there were 40,377 shares available for grant under the 2021 Plan. Stock Award Activity The following table summarizes the status of the Company’s non-vested restricted stock awards for the three months ended March 31, 2024: Non-vested Number of Weighted Outstanding at December 31, 2023 7,875 $ 10.96 Granted - - Vested (6,875 ) 8.30 Forfeited - - Outstanding at March 31, 2024 1,000 $ 25.80 In February 2023, the Company issued 18,734 fully vested restricted stock units to certain employees in lieu of cash to satisfy their 2022 bonuses of which 6,546 shares were withheld for tax liabilities with a fair value of $57,588. The number of restricted stock unit awards issued were determined based on the approved bonus amount divided by the market price of the Company’s common stock on the date of grant. The value of fully vested restricted stock unit awards issued is recorded as stock compensation expense on the date of grant with a reversal of the related accrued bonus recorded in 2022. The following is a summary of stock option activity for the three months ended March 31, 2024: Number of Weighted Weighted Aggregate Outstanding at December 31, 2023 29,770 $ 36.51 6.5 $ - Granted - - - - Exercised - - - - Cancelled and forfeited - - - - Outstanding at March 31, 2024 29,770 $ 36.51 6.3 $ - Exercisable at March 31, 2024 26,209 $ 36.51 6.3 $ - There were no options granted during the three months ended March 31, 2024 The weighted average grant date fair value of options granted during the three months ended March 31, 2023 was $0.44 per share. The Company calculated the grant-date fair value of stock option awards granted during the three months ended March 31, 2023 using the Black-Scholes model with the following assumptions: Risk-free interest rate 3.63 % Expected dividend yield 0.00 % Volatility factor 108.78 % Expected life of option (in years) 6.0 % Stock-Based Compensation Expense For the three months ended March 31, 2024 and 2023, the Company recorded stock-based compensation expense as follows: Three Months Ended 2024 2023 Research and development $ 4,845 $ 44,845 General and administrative 7,029 159,584 Sales and marketing - 15,160 Total stock-based compensation $ 11,874 $ 219,589 At March 31, 2024, there was approximately $12,609 of unrecognized compensation expense related to non-vested stock option awards that are expected to be recognized over a weighted-average period of 0.91 years. At March 31, 2024, there was approximately $6,331 of unrecognized compensation expense related to non-vested restricted stock awards that are expected to be recognized over a weighted-average period of 0.50 years.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	6. RELATED PARTY TRANSACTIONS NanoHybrids, LLC In December 2021, the Company entered into an agreement with NanoHybrids, LLC (“NanoHybrids”) to utilize the Company’s research and development staff and laboratory facility when available to perform work for NanoHybrids. Any hours worked by Company employees for NanoHybrids are billed to NanoHybrids at a bill rate of the respective employee’s fully burdened personnel cost plus 10%. Additionally, the Company may purchase certain lab supplies for NanoHybrids and rebill these costs to NanoHybrids. NanoHybrids is majority owned by the Company’s Chief Technology Officer. The table below summarizes the amounts earned and due from NanoHybrids as of and for the three-month periods’ ended March 31, 2024 and 2023, and balances due as of March 31, 2024 and December 31, 2023: Three Months Ended 2024 2023 Income from NanoHybrids included in Other Income $ 73,591 $ 95,798 Cash receipts from NanoHybrids $ - $ 19,731 As of March 31, December 31, Amounts receivable from NanoHybrids included in Prepaids and Other Current Assets $ 73,591 $ 41,269

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2024
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	7. PROPERTY AND EQUIPMENT Property and equipment consisted of the following at March 31, 2024 and December 31, 2023: Depreciable March 31, December 31, Construction-in-process $ 1,088,255 $ 1,052,822 Furniture, fixtures, and equipment 3-5 years 141,164 141,164 Software 3-5 years 4,457 4,457 Lab equipment 3-5 years 1,287,783 1,287,783 Leasehold improvements Shorter of useful life or life of lease 43,231 43,231 2,564,890 2,529,457 Less: accumulated depreciation (1,263,430 ) (1,243,716 ) Property and equipment, net $ 1,301,460 $ 1,285,741 The Company reviews long-lived assets for impairment when events, expectations, or changes in circumstances indicate that the asset’s carrying value may not be recoverable. As a result of this review in 2023, the Company revised the useful life of certain lab equipment in the first quarter of 2023 due to a change in expectations of the time the equipment will be used which resulted in approximately $45,000 of additional depreciation recorded in the three months ended March 31, 2023.

Leases

Leases	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
LEASES	8. LEASES The Company has lease arrangements for office, laboratory space and copiers. A summary of supplemental lease information is as follows: Three Months Ended March 31, March 31, Weighted average remaining lease term – operating leases (in years) 2.7 3.5 Weighted average remaining lease term – finance leases (in years) 3.9 4.8 Weighted average discount rate 7.0 % 7.0 % Operating cash flows from operating leases $ 44,214 $ 43,564 Operating cash flows from finance leases $ 4,807 $ 1,202 A summary of the Company’s lease assets and liabilities are as follows: March 31, December 31, Operating lease right-of-use asset $ 298,655 $ 333,267 Finance lease asset – property & equipment, net 13,970 15,152 Total lease assets 312,625 348,419 Current portion of operating lease liability 145,811 162,990 Current portion of finance lease liability included in accrued expenses 4,807 4,807 Non-current portion of operating lease liabilities 170,703 189,987 Non-current portion of finance lease liabilities included in other non-current liabilities 11,407 12,321 Total lease liabilities $ 332,728 $ 370,105 A summary of the Company’s estimated operating lease payments are as follows: Year 2024 (1) $ 120,812 2025 100,000 2026 100,000 2027 25,000 2028 - Thereafter - Total future lease payments 345,812 Less: Imputed interest 29,298 Present value of lease liability $ 316,514 (1) Excludes the three months ended March 31, 2024

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	9. COMMITMENTS AND CONTINGENCIES Minimum Royalties As required under the License Agreement (see Note 3), following the first sale of Cartridges, the Company will also make royalty payments to Toray equal to 7.5% of the net sales of the Cartridges for a term of 10 years. A 50% reduction in the royalty rate applies upon expiry of applicable Toray patents on a product-by-product and country-by-country basis. There were no sales of or revenues from the Cartridges through March 31, 2024. Indemnification The Company has certain agreements with service providers with which it does business that contain indemnification provisions pursuant to which the Company typically agrees to indemnify the party against certain types of third-party claims. The Company accrues for known indemnification issues when a loss is probable and can be reasonably estimated. The Company would also accrue for estimated incurred but unidentified indemnification issues based on historical activity. As the Company has not incurred any indemnification losses to date, there were no accruals for or expenses related to indemnification issues for any period presented.

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	3 Months Ended
	Mar. 31, 2024
Supplemental Balance Sheet Information [Abstract]
SUPPLEMENTAL BALANCE SHEET INFORMATION	10. SUPPLEMENTAL BALANCE SHEET INFORMATION Prepaid expenses and other current assets consist of the following: March 31, December 31, Prepaid insurance $ 37,090 $ 136,342 Vendor prepayments 538,019 558,959 Prepaid other 213,469 51,962 Total prepaid expenses and other current assets $ 788,578 $ 747,263 Accrued expenses and other current liabilities consist of the following: March 31, December 31, Accrued personnel costs $ 519,377 $ 566,087 Good received but unpaid 8,066 78,579 Accrued expenses for CFO separation agreement 20,000 160,000 Accrued legal fees 107,570 157,670 Accrued clinical trial expenses 350,620 - Accrued other 102,472 154,575 Total accrued expenses and other current liabilities $ 1,108,105 $ 1,116,911

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (2,328,465)	$ (2,539,843)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2024
Significant Accounting Policies [Abstract]
Use of Estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in these condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. The Company believes judgment is involved in accounting for the fair value-based measurement of stock-based compensation, accruals, and warrants. The Company evaluates its estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the condensed consolidated financial statements.
Stock-Based Compensation	Stock-based compensation Stock-based compensation expense for all stock-based payment awards made to employees, directors and non-employees is measured based on the grant-date fair value of the award. Stock-based compensation expense for awards granted to non-employees is determined using the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. The Company uses the Black-Scholes option pricing model to determine the fair value of options granted. The Company recognizes the compensation cost of stock-based awards on a straight-line basis over the requisite service period. For stock awards for which vesting is subject to performance-based milestones, the expense is recorded over the implied service period after the point when the achievement of the milestone is probable, or the performance condition has been achieved. The Company recognizes forfeitures related to employee stock-based payments when they occur. Forfeited options are recorded as a reduction to stock compensation expense.
Research and Development Expenses	Research and development expenses Costs incurred in the research and development of new products are expensed as incurred. Research and development costs include, but are not limited to, salaries, benefits, stock-based compensation, laboratory supplies, fees for professional service providers and costs associated with product development efforts, including preclinical studies and clinical trials. The Company estimates preclinical study and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf.
Segment Reporting	Segment Reporting Management has determined that the Company has one operating segment, which is consistent with the Company structure and how it manages the business. As of March 31, 2024 and December 31, 2023, the majority of the Company’s assets were located in the United States.
Net Loss per Share	Net Loss per Share Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, convertible notes, options outstanding under the Company’s stock option plan and warrants. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive. Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti -dilutive are as follows (in common stock equivalent shares): Potentially Dilutive Securities Listing: March 31, 2024 2023 Options to purchase common stock 29,770 36,992 Restricted stock units (RSUs) 1,000 9,875 Warrants for common stock 271,714 40,594 Class A warrants for common stock 124,200 124,200 Class B warrants for common stock 3,770 3,770 5-Year warrants for common stock 2,692,308 - Prefunded warrants for common stock 1,243,000 -
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This amends the ASC 815 Derivatives and Hedging—Contracts in Entity’s Own Equity to simplify the guidance on (1) accounting for convertible instruments, and (2) the derivatives scope exception for contracts in an entity’s own equity. The guidance on earnings per share (“EPS”) has also been amended to simplify the calculations and make them more internally consistent. The Company adopted this new standard on January 1, 2024. The new standard had no impact on the Company’s condensed consolidated financial statements.
Recently Issued Accounting Standards	Recently Issued Accounting Standards The Company does not believe that any recently issued but not yet effective accounting pronouncements will have a material effect on the accompanying unaudited condensed consolidated financial statements.

Significant Accounting Polici_2

Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2024
Significant Accounting Policies [Abstract]
Schedule of Diluted Net Loss Per Share	Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti -dilutive are as follows (in common stock equivalent shares): Potentially Dilutive Securities Listing: March 31, 2024 2023 Options to purchase common stock 29,770 36,992 Restricted stock units (RSUs) 1,000 9,875 Warrants for common stock 271,714 40,594 Class A warrants for common stock 124,200 124,200 Class B warrants for common stock 3,770 3,770 5-Year warrants for common stock 2,692,308 - Prefunded warrants for common stock 1,243,000 -

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2024
Warrants [Abstract]
Schedule of Information with Regard to Warrants Outstanding	The following table summarizes information with regard to warrants outstanding at March 31, 2024: Shares Exercisable for Weighted Weighted January 2024 Common Stock Warrants 2,692,308 Common Stock $ 1.30 4.8 January 2024 Placement Agent Warrants 188,462 Common Stock $ 1.625 4.8 January 2024 Prefunded Warrants 1,243,000 Common Stock $ 0.0001 – August 2023 Common Stock Warrants 216,000 Common Stock $ 7.365 4.4 August 2023 Placement Agent Warrants 15,120 Common Stock $ 9.2063 4.4 Class A Warrants 124,200 Common Stock $ 140.00 2.6 Class B Warrants 3,770 Common Stock $ 200.00 2.6 Other Pre-2024 Common Stock Warrants 40,594 Common Stock $ 64.73 1.9

Stock Compensation (Tables)

Stock Compensation (Tables)	3 Months Ended
	Mar. 31, 2024
Stock Compensation [Abstract]
Schedule of Non-vested Restricted Stock	The following table summarizes the status of the Company’s non-vested restricted stock awards for the three months ended March 31, 2024: Non-vested Number of Weighted Outstanding at December 31, 2023 7,875 $ 10.96 Granted - - Vested (6,875 ) 8.30 Forfeited - - Outstanding at March 31, 2024 1,000 $ 25.80
Schedule of Stock Option Activity	The following is a summary of stock option activity for the three months ended March 31, 2024: Number of Weighted Weighted Aggregate Outstanding at December 31, 2023 29,770 $ 36.51 6.5 $ - Granted - - - - Exercised - - - - Cancelled and forfeited - - - - Outstanding at March 31, 2024 29,770 $ 36.51 6.3 $ - Exercisable at March 31, 2024 26,209 $ 36.51 6.3 $ -
Schedule of Grant-Date Fair Value of Stock Option Awards Granted	The weighted average grant date fair value of options granted during the three months ended March 31, 2023 was $0.44 per share. The Company calculated the grant-date fair value of stock option awards granted during the three months ended March 31, 2023 using the Black-Scholes model with the following assumptions: Risk-free interest rate 3.63 % Expected dividend yield 0.00 % Volatility factor 108.78 % Expected life of option (in years) 6.0 %
Schedule of Stock-Based Compensation Expense	For the three months ended March 31, 2024 and 2023, the Company recorded stock-based compensation expense as follows: Three Months Ended 2024 2023 Research and development $ 4,845 $ 44,845 General and administrative 7,029 159,584 Sales and marketing - 15,160 Total stock-based compensation $ 11,874 $ 219,589

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
Schedule of Due from Related Parties	The table below summarizes the amounts earned and due from NanoHybrids as of and for the three-month periods’ ended March 31, 2024 and 2023, and balances due as of March 31, 2024 and December 31, 2023: Three Months Ended 2024 2023 Income from NanoHybrids included in Other Income $ 73,591 $ 95,798 Cash receipts from NanoHybrids $ - $ 19,731
Schedule of Balance Due	As of March 31, December 31, Amounts receivable from NanoHybrids included in Prepaids and Other Current Assets $ 73,591 $ 41,269

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2024
Property and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment consisted of the following at March 31, 2024 and December 31, 2023: Depreciable March 31, December 31, Construction-in-process $ 1,088,255 $ 1,052,822 Furniture, fixtures, and equipment 3-5 years 141,164 141,164 Software 3-5 years 4,457 4,457 Lab equipment 3-5 years 1,287,783 1,287,783 Leasehold improvements Shorter of useful life or life of lease 43,231 43,231 2,564,890 2,529,457 Less: accumulated depreciation (1,263,430 ) (1,243,716 ) Property and equipment, net $ 1,301,460 $ 1,285,741

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Schedule of Lease Arrangements for Office, Laboratory Space and Copiers	The Company has lease arrangements for office, laboratory space and copiers. A summary of supplemental lease information is as follows: Three Months Ended March 31, March 31, Weighted average remaining lease term – operating leases (in years) 2.7 3.5 Weighted average remaining lease term – finance leases (in years) 3.9 4.8 Weighted average discount rate 7.0 % 7.0 % Operating cash flows from operating leases $ 44,214 $ 43,564 Operating cash flows from finance leases $ 4,807 $ 1,202
Schedule of Lease Assets and Liabilities	A summary of the Company’s lease assets and liabilities are as follows: March 31, December 31, Operating lease right-of-use asset $ 298,655 $ 333,267 Finance lease asset – property & equipment, net 13,970 15,152 Total lease assets 312,625 348,419 Current portion of operating lease liability 145,811 162,990 Current portion of finance lease liability included in accrued expenses 4,807 4,807 Non-current portion of operating lease liabilities 170,703 189,987 Non-current portion of finance lease liabilities included in other non-current liabilities 11,407 12,321 Total lease liabilities $ 332,728 $ 370,105
Schedule of Estimated Operating Lease Payments	A summary of the Company’s estimated operating lease payments are as follows: Year 2024 (1) $ 120,812 2025 100,000 2026 100,000 2027 25,000 2028 - Thereafter - Total future lease payments 345,812 Less: Imputed interest 29,298 Present value of lease liability $ 316,514 (1) Excludes the three months ended March 31, 2024

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	3 Months Ended
	Mar. 31, 2024
Supplemental Balance Sheet Information [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following: March 31, December 31, Prepaid insurance $ 37,090 $ 136,342 Vendor prepayments 538,019 558,959 Prepaid other 213,469 51,962 Total prepaid expenses and other current assets $ 788,578 $ 747,263
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following: March 31, December 31, Accrued personnel costs $ 519,377 $ 566,087 Good received but unpaid 8,066 78,579 Accrued expenses for CFO separation agreement 20,000 160,000 Accrued legal fees 107,570 157,670 Accrued clinical trial expenses 350,620 - Accrued other 102,472 154,575 Total accrued expenses and other current liabilities $ 1,108,105 $ 1,116,911

Nature of Operations and Basi_2

Nature of Operations and Basis of Presentation (Details) - USD ($)			3 Months Ended
	May 09, 2024	Feb. 28, 2024	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Nature of Operations and Basis of Presentation (Details) [Line Items]
Market value held securities	$ 1,000,000
Common stock closing bid price (in Dollars per share)		$ 1
Trading price per share (in Dollars per share)			$ 1
Held in common stock	$ 1,250,000
Reverse stock split			On July 24, 2023, the Company executed a reverse stock split of its shares of common stock at a ratio of 1-for-20 (the “Reverse Stock Split”), with a corresponding reduction in the number of authorized outstanding number of shares of common stock from 100,000,000 to 7,500,000. The Reverse Stock Split became effective on July 24, 2023. All of the Company’s 2023 historical share and per share information related to issued and outstanding common stock and outstanding options and warrants exercisable for common stock in these financial statements have been adjusted, on a retroactive basis, to reflect this 1-for-20 reverse stock split.
Cash and cash equivalents			$ 2,661,169		$ 2,208,516
Current liabilities			1,525,741		$ 1,771,375
Net cash used in operating activities			$ (2,296,076)	$ (2,933,607)
Nasdaq Stock Market LLC [Member]
Nature of Operations and Basis of Presentation (Details) [Line Items]
Common stock price (in Dollars per share)			$ 1
Market value held securities			$ 1,000,000
Common stock closing bid price (in Dollars per share)			$ 1
IPO [Member]
Nature of Operations and Basis of Presentation (Details) [Line Items]
Cash and cash equivalents			$ 2,700,000
Current liabilities			$ 1,500,000

Significant Accounting Polici_3

Significant Accounting Policies (Details)	3 Months Ended
	Mar. 31, 2024
Summary of Significant Accounting Policies [Line Items]
Operating segment	1

Significant Accounting Polici_4

Significant Accounting Policies (Details) - Schedule of Diluted Net Loss Per Share - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	29,770	36,992
Restricted stock units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	1,000	9,875
Warrants for Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	271,714	40,594
Class A warrants for common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	124,200	124,200
Class B warrants for common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	3,770	3,770
5 Year Warrants for Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	2,692,308
Prefunded warrants for common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	1,243,000

License and Supply Agreement _2

License and Supply Agreement with Toray Industries (Details)	Oct. 23, 2023
License and Supply Agreement with Toray Industries [Line Items]
License term	10 years
Royalty percentage	50%
Maximum [Member]
License and Supply Agreement with Toray Industries [Line Items]
License agreement	15%
Minimum [Member]
License and Supply Agreement with Toray Industries [Line Items]
License agreement	7.50%

Warrants (Details)

Warrants (Details) - USD ($)		3 Months Ended
	Jan. 02, 2024	Mar. 31, 2024
Warrants [Line Items]
Aggregate shares	2,692,308
Exercise price (in Dollars per share)	$ 1.3
Public offering price (in Dollars per share)	1.3
Prefunded warrant price per share (in Dollars per share)	$ 1.2999
Warrants exercisable term		5 years
Cash fee (in Dollars)		$ 245,000
Gross proceeds percentage		1%
Management fee (in Dollars)		$ 35,000
Aggregate percentage		7%
Exercise percentage		125%
Prefunded warrants on exercised		911,540
H.C. Wainwright & Co., LLC [Member]
Warrants [Line Items]
Gross proceeds percentage		7%
Prefunded Warrants [Member]
Warrants [Line Items]
Shares of common stock	537,768
Aggregate share	2,154,540
January 2024 Placement Agent Warrants [Member]
Warrants [Line Items]
Exercise price (in Dollars per share)		$ 1.625
Prefunded warrant price per share (in Dollars per share)		$ 1.625
Warrants exercisable term		4 years 9 months 18 days
Aggregate warrant share		188,462
Warrant [Member]
Warrants [Line Items]
Prefunded warrants on exercised		216,000

Warrants (Details) - Schedule o

Warrants (Details) - Schedule of Information with Regard to Warrants Outstanding	3 Months Ended
	Mar. 31, 2024 $ / shares shares
January 2024 Common Stock Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding Shares | shares	2,692,308
Warrants outstanding Exercisable for	Common Stock
Warrants outstanding Weighted Average Exercise Price | $ / shares	$ 1.3
Warrants outstanding Weighted Average Remaining Life (in Years)	4 years 9 months 18 days
January 2024 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding Shares | shares	188,462
Warrants outstanding Exercisable for	Common Stock
Warrants outstanding Weighted Average Exercise Price | $ / shares	$ 1.625
Warrants outstanding Weighted Average Remaining Life (in Years)	4 years 9 months 18 days
January 2024 Prefunded Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding Shares | shares	1,243,000
Warrants outstanding Exercisable for	Common Stock
Warrants outstanding Weighted Average Exercise Price | $ / shares	$ 0.0001
Warrants outstanding Weighted Average Remaining Life (in Years)
August 2023 Common Stock Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding Shares | shares	216,000
Warrants outstanding Exercisable for	Common Stock
Warrants outstanding Weighted Average Exercise Price | $ / shares	$ 7.365
Warrants outstanding Weighted Average Remaining Life (in Years)	4 years 4 months 24 days
August 2023 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding Shares | shares	15,120
Warrants outstanding Exercisable for	Common Stock
Warrants outstanding Weighted Average Exercise Price | $ / shares	$ 9.2063
Warrants outstanding Weighted Average Remaining Life (in Years)	4 years 4 months 24 days
Class A Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding Shares | shares	124,200
Warrants outstanding Exercisable for	Common Stock
Warrants outstanding Weighted Average Exercise Price | $ / shares	$ 140
Warrants outstanding Weighted Average Remaining Life (in Years)	2 years 7 months 6 days
Class B Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding Shares | shares	3,770
Warrants outstanding Exercisable for	Common Stock
Warrants outstanding Weighted Average Exercise Price | $ / shares	$ 200
Warrants outstanding Weighted Average Remaining Life (in Years)	2 years 7 months 6 days
Other Pre-2024 Common Stock Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding Shares | shares	40,594
Warrants outstanding Exercisable for	Common Stock
Warrants outstanding Weighted Average Exercise Price | $ / shares	$ 64.73
Warrants outstanding Weighted Average Remaining Life (in Years)	1 year 10 months 24 days

Stock Compensation (Details)

Stock Compensation (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Feb. 28, 2023
Stock Compensation [Line Items]
Vested restricted stock units			18,734
Employees shares	6,546
Tax liabilities (in Dollars)	$ 57,588
Weighted average grant date fair value of options granted (in Dollars per share)		$ 0.44
Non-Vested Restricted Stock Awards [Member]
Stock Compensation [Line Items]
Unrecognized compensation expense (in Dollars)	$ 6,331
Weighted-average period	6 months
Non-Vested Stock Option [Member]
Stock Compensation [Line Items]
Unrecognized compensation expense (in Dollars)	$ 12,609
Weighted-average period	10 months 28 days
2018 Stock Incentive Plan [Member]
Stock Compensation [Line Items]
Number of shares of common stock reserved for issuance	31,472
Shares available for grants	13,113
2021 Incentive Plan [Member]
Stock Compensation [Line Items]
Number of shares of common stock reserved for issuance	98,000
Shares available for grants	40,377

Stock Compensation (Details) -

Stock Compensation (Details) - Schedule of Non-vested Restricted Stock - Non-vested Restricted Stock Awards [Member]	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Schedule of Non-vested Restricted Stock [Line Items]
Number of Shares, Outstanding at beginning balance | shares	7,875
Weighted Average Grant Date Fair Value, Outstanding at beginning balance | $ / shares	$ 10.96
Number of Shares, Granted | shares
Weighted Average Grant Date Fair Value, Granted | $ / shares
Number of Shares, Vested | shares	(6,875)
Weighted Average Grant Date Fair Value, Vested | $ / shares	$ 8.3
Number of Shares, Cancelled / forfeited | shares
Weighted Average Grant Date Fair Value, Cancelled / forfeited | $ / shares
Number of Shares, Outstanding at ending balance | shares	1,000
Weighted Average Grant Date Fair Value, Outstanding at ending balance | $ / shares	$ 25.8

Stock Compensation (Details) _2

Stock Compensation (Details) - Schedule of Stock Option Activity - USD ($)		3 Months Ended
	Dec. 31, 2023	Mar. 31, 2024
Schedule of Stock Option Activity [Abstract]
Number of Stock Options, Outstanding at beginning balance	29,770
Weighted Average Exercise Price Per Share, Outstanding at beginning balance (in Dollars per share)	$ 36.51
Weighted Average Remaining Contractual Life in Years, Outstanding at beginning balance	6 years 6 months
Aggregate Intrinsic Value, Outstanding at beginning balance (in Dollars)
Number of Stock Options, Outstanding at ending balance		29,770
Weighted Average Exercise Price Per Share, Outstanding at ending balance (in Dollars per share)		$ 36.51
Weighted Average Remaining Contractual Life in Years, Outstanding at ending balance		6 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding at ending balance (in Dollars)
Number of Stock Options, Exercisable		26,209
Weighted Average Exercise Price Per Share, Exercisable (in Dollars per share)		$ 36.51
Weighted Average Remaining Contractual Life in Years, Exercisable		6 years 3 months 18 days
Aggregate Intrinsic Value, Exercisable (in Dollars)
Number of Stock Options, Granted
Weighted Average Exercise Price Per Share, Granted (in Dollars per share)
Weighted Average Remaining Contractual Life in Years, Granted
Aggregate Intrinsic Value. Granted
Number of Stock Options, Exercised
Weighted Average Exercise Price Per Share, Exercised (in Dollars per share)
Weighted Average Remaining Contractual Life in Years, Exercised
Aggregate Intrinsic Value, Exercised
Number of Stock Options, Cancelled and forfeited
Weighted Average Exercise Price Per Share, Cancelled and forfeited (in Dollars per share)
Weighted Average Remaining Contractual Life in Years, Cancelled and forfeited
Aggregate Intrinsic Value, Cancelled and forfeited

Stock Compensation (Details) _3

Stock Compensation (Details) - Schedule of Grant-Date Fair Value of Stock Option Awards Granted	3 Months Ended
	Mar. 31, 2024
Schedule of Grant-Date Fair Value of Stock Option Awards Granted [Abstract]
Risk-free interest rate	3.63%
Expected dividend yield	0%
Volatility factor	108.78%
Expected life of option (in years)	6 years

Stock Compensation (Details) _4

Stock Compensation (Details) - Schedule of Stock-Based Compensation Expense - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Stock-Based Compensation Expense [Line Items]
Total stock-based compensation	$ 11,874	$ 219,589
Research and development [Member]
Schedule of Stock-Based Compensation Expense [Line Items]
Total stock-based compensation	4,845	44,845
General and administrative [Member]
Schedule of Stock-Based Compensation Expense [Line Items]
Total stock-based compensation	7,029	159,584
Sales and marketing [Member]
Schedule of Stock-Based Compensation Expense [Line Items]
Total stock-based compensation		$ 15,160

Related Party Transactions (Det

Related Party Transactions (Details)	12 Months Ended
	Dec. 31, 2021
NanoHybrids Inc. [Member]
Related Party Transactions [Line Items]
Bill rate additional cost percentage	10%

Related Party Transactions (D_2

Related Party Transactions (Details) - Schedule of Due from Related Parties - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income from NanoHybrids included in Other Income [Member]
Schedule of Due from Related Parties [Line Items]
Due from NanoHybrids	$ 73,591	$ 95,798
Cash receipts from NanoHybrids [Member]
Schedule of Due from Related Parties [Line Items]
Due from NanoHybrids		$ 19,731

Related Party Transactions (D_3

Related Party Transactions (Details) - Schedule of Balance Due - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Schedule of Balance Due [Line Items]
Amounts receivable from NanoHybrids included in Prepaids and Other Current Assets	$ 73,591	$ 41,269

Property and Equipment (Details

Property and Equipment (Details)	3 Months Ended
	Mar. 31, 2023 USD ($)
Property and Equipment [Line Items]
Additional depreciation	$ 45,000

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of Property and Equipment, Net - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, Gross	$ 2,564,890	$ 2,529,457
Less: accumulated depreciation	(1,263,430)	(1,243,716)
Property and equipment, net	1,301,460	1,285,741
Construction-in-process [Member]
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, Gross	1,088,255	1,052,822
Furniture, fixtures, and equipment [Member]
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, Gross	141,164	141,164
Software [Member]
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, Gross	4,457	4,457
Lab equipment [Member]
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, Gross	1,287,783	1,287,783
Leasehold improvements [Member]
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, Gross	$ 43,231	$ 43,231
Property and equipment, depreciable lives, description	Shorter of useful life or life of lease
Minimum [Member] | Furniture, fixtures, and equipment [Member]
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, depreciable lives	3 years
Minimum [Member] | Software [Member]
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, depreciable lives	3 years
Minimum [Member] | Lab equipment [Member]
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, depreciable lives	3 years
Maximum [Member] | Furniture, fixtures, and equipment [Member]
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, depreciable lives	5 years
Maximum [Member] | Software [Member]
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, depreciable lives	5 years
Maximum [Member] | Lab equipment [Member]
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, depreciable lives	5 years

Leases (Details) - Schedule of

Leases (Details) - Schedule of Lease Arrangements for Office, Laboratory Space and Copiers - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Lease Arrangements for Office, Laboratory Space and Copiers [Abstract]
Weighted average remaining lease term – operating leases (in years)	2 years 8 months 12 days	3 years 6 months
Weighted average remaining lease term – finance leases (in years)	3 years 10 months 24 days	4 years 9 months 18 days
Weighted average discount rate	7%	7%
Operating cash flows from operating leases	$ 44,214	$ 43,564
Operating cash flows from finance leases	$ 4,807	$ 1,202

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Lease Assets and Liabilities - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Schedule of Lease Assets and Liabilities [Abstract]
Operating lease right-of-use asset	$ 298,655	$ 333,267
Finance lease asset – property & equipment, net	13,970	15,152
Total lease assets	312,625	348,419
Current portion of operating lease liability	145,811	162,990
Current portion of finance lease liability included in accrued expenses	4,807	4,807
Non-current portion of operating lease liabilities	170,703	189,987
Non-current portion of finance lease liabilities included in other non-current liabilities	11,407	12,321
Total lease liabilities	$ 332,728	$ 370,105

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of Estimated Operating Lease Payments	Dec. 31, 2023 USD ($)
Schedule of Estimated Operating Lease Payments [Abstract]
2024	$ 120,812	[1]
2025	100,000
2026	100,000
2027	25,000
2028
Thereafter
Total future lease payments	345,812
Less: Imputed interest	29,298
Present value of lease liability	$ 316,514
[1] Excludes the three months ended March 31, 2024

Commitments and Contingencies (

Commitments and Contingencies (Details)	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies [Line Items]
Royalty payments percentage	7.50%
Net sales of the cartridges for the period	10 years
Royalty rate percentage	50%

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information (Details) - Schedule of Prepaid Expenses and Other Current Assets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Schedule of Prepaid Expenses and Other Current Assets [Abstract]
Prepaid insurance	$ 37,090	$ 136,342
Vendor prepayments	538,019	558,959
Prepaid other	213,469	51,962
Total prepaid expenses and other current assets	$ 788,578	$ 747,263

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information (Details) - Schedule of Accrued Expenses and Other Current Liabilities - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Schedule of Accrued Expenses and Other Current Liabilities [Abstract]
Accrued personnel costs	$ 519,377	$ 566,087
Good received but unpaid	8,066	78,579
Accrued expenses for CFO separation agreement	20,000	160,000
Accrued legal fees	107,570	157,670
Accrued clinical trial expenses	350,620
Accrued other	102,472	154,575
Total accrued expenses and other current liabilities	$ 1,108,105	$ 1,116,911